This information is intended for use by health professionals

1. Name of the medicinal product

Pancrex V Powder

2. Qualitative and quantitative composition

Pancreatin BP to provide enzymatic activity per gram not less than:

Free protease

1400 BP units


25000 BP units


30000 BP units

3. Pharmaceutical form


4. Clinical particulars
4.1 Therapeutic indications

Pancrex is used to compensate for reduced intestinal enzyme activity in pancreatic deficiency states.

It is indicated for the treatment of fibrocystic disease of the pancreas (cystic fibrosis), chronic pancreatitis and pancreatic steatorrhoea following pancreatectomy. It may also be indicated following gastrectomy as an aid to digestion.

4.2 Posology and method of administration


Dosage should be adjusted according to the needs of the individual patient and the amount and type of food consumed. The following dosage ranges provide a suitable basis for adjustment.

Adults, the Elderly, and Children

0.5 g - 2 g swallowed dry or mixed with a little water or milk before each snack or meal.

New-born infants

0.25 g - 0.5 g with each feed.

Method of administration

(1) Oral

(2) Pancrex V Powder may be administered via a nasogastric tube or a gastrostomy tube. Refer to relevant local and national official guidelines (see section 4.4).

4.3 Contraindications

Hypersensitivity to the active ingredient (porcine pancreatin) or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

It is possible that some irritation of the skin of the mouth may occur if the powder is retained in the mouth. Irritation of the anus may also occur. A barrier cream may prevent this local irritation.

Allergic/asthmatic reactions have occasionally occurred on handling the powder.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicine.

If the powder is mixed with liquids or feeds the resulting mixture should not be allowed to stand for more than one hour prior to use.

When Pancrex V Powder is administered via a nasogastric tube or a gastrostomy tube then the internal diameter of the tube must be adequate and patency of the tube must be ensured. Refer to relevant local and national official guidelines.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Fertility, pregnancy and lactation

Pancrex should not be used in pregnancy and lactation unless clearly necessary but if required should be used in doses sufficient to provide adequate nutritional status.

4.7 Effects on ability to drive and use machines


4.8 Undesirable effects

Rare cases of hyperuricosuria and hyperuricaemia have been reported when extremely high doses of pancreatin have been taken.

Strictures of the ileo-caecum and large bowel, and colitis, have been reported in children with cystic fibrosis taking high doses of pancreatic enzyme supplements. To date Pancrex and Pancrex V presentations have not been implicated in the development of colonic damage. However unusual abdominal symptoms or changes in abdominal symptoms should be reviewed to exclude the possibility of colonic damage especially if the patient is taking in excess of 10,000 units/kg/day of lipase.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:

4.9 Overdose

None stated.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pancreatin is derived from porcine pancreas and contains the enzymes, amylase, protease and lipase. The enzymes have the same actions as pancreatic juice and when administered to patients with pancreatic insufficiency improve the ability to metabolise starches, proteins and fats.

5.2 Pharmacokinetic properties

Pancreatin hydrolyses fats to glycerol and fatty acids, changes proteins into proteases and derived substances, and converts starch into dextrins and sugars.

5.3 Preclinical safety data

No relevant pre-clinical safety data has been generated.

6. Pharmaceutical particulars
6.1 List of excipients

Lactose monohydrate.

6.2 Incompatibilities

None known.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

Securitainer: 100 g, 250 g and 300 g.

6.6 Special precautions for disposal and other handling

Not applicable.

7. Marketing authorisation holder

Essential Pharmaceuticals Limited

Unit 7, Egham Business Village

Crabtree Road


Surrey TW20 8RB,


8. Marketing authorisation number(s)

PL 41094/0004

9. Date of first authorisation/renewal of the authorisation

13/11/1985 / 28/11/2003

10. Date of revision of the text